Summary of QDII Fund Performance in November Core Insights - In November, out of 687 comparable QDII funds, 31.1% (214 funds) saw an increase in net value, while 470 funds experienced a decline, and 3 funds remained unchanged [1] - The top-performing QDII fund was the Chuangjin Hexin Global Pharmaceutical Biotechnology Fund, which achieved a return of 14.29% [1] - The overall performance of QDII funds was mixed, with significant variations in returns across different sectors, particularly in biotechnology and healthcare [2][3] Group 1: Fund Performance - 14 QDII funds had returns exceeding 8% in November, with the Chuangjin Hexin Global Pharmaceutical Biotechnology Fund leading at 14.29% [1] - The largest fund by size among those with over 8% returns was the Harvest S&P Biotechnology Select Industry ETF, with a scale of 2.209 billion yuan and a return of 8.57% [2] - Other notable funds included the GF Global Healthcare Fund A (USD) and the Huatai-PB Nasdaq Biotechnology ETF, with returns of 8.22% and 8.21% respectively [2] Group 2: Fund Details - The Chuangjin Hexin Global Pharmaceutical Biotechnology Fund, established on November 17, 2023, reported a year-to-date return of 97.34% and a cumulative net value of 1.7974 yuan [1] - The Harvest S&P Biotechnology Select Industry ETF, established on December 26, 2023, had a year-to-date return of 29.47% and a cumulative net value of 1.2525 yuan [2] - The top ten holdings of the Chuangjin Hexin fund included companies like Cidar, Anapt, and Taysh, focusing on the innovative drug industry [1] Group 3: Sector Performance - Funds tracking the Hang Seng Internet Technology Index and the China Securities Korea Exchange Semiconductor Index performed poorly, contributing to the decline of several QDII funds [3] - The overall trend indicates a strong performance in the biotechnology sector, while technology-focused funds faced challenges [3]